These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16630031)

  • 1. Knowledge, attitudes and health outcomes in HIV-infected travellers to the USA.
    Mahto M; Ponnusamy K; Schuhwerk M; Richens J; Lambert N; Wilkins E; Churchill DR; Miller RF; Behrens RH
    HIV Med; 2006 May; 7(4):201-4. PubMed ID: 16630031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Travel patterns and risk behaviour of HIV-positive people travelling internationally.
    Salit IE; Sano M; Boggild AK; Kain KC
    CMAJ; 2005 Mar; 172(7):884-8. PubMed ID: 15795409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV and travel.
    Schuhwerk MA; Richens J; Zuckerman JN
    Travel Med Infect Dis; 2006; 4(3-4):174-83. PubMed ID: 16887739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand.
    Apisarnthanarak A; Jirayasethpong T; Sa-nguansilp C; Thongprapai H; Kittihanukul C; Kamudamas A; Tungsathapornpong A; Mundy LM
    HIV Med; 2008 May; 9(5):322-5. PubMed ID: 18400079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successive switching of antiretroviral therapy is associated with high psychological and physical burden.
    Sherr L; Lampe F; Norwood S; Leake-Date H; Fisher M; Edwards S; Arthur G; Anderson J; Zetler S; Johnson M; Harding R
    Int J STD AIDS; 2007 Oct; 18(10):700-4. PubMed ID: 17945049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection.
    Huang HY; Daar ES; Sax PE; Young B; Cook P; Benson P; Cohen C; Scribner A; Hu H
    HIV Med; 2008 May; 9(5):285-93. PubMed ID: 18400075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment perceptions and attitudes of older human immunodeficiency virus-infected adults.
    Wutoh AK; Brown CM; Dutta AP; Kumoji EK; Clarke-Tasker V; Xue Z
    Res Social Adm Pharm; 2005 Mar; 1(1):60-76. PubMed ID: 17138466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting antiretroviral drug adherence among HIV/AIDS adult patients attending HIV/AIDS clinic at Moi Teaching and Referral Hospital, Eldoret, Kenya.
    Talam NC; Gatongi P; Rotich J; Kimaiyo S
    East Afr J Public Health; 2008 Aug; 5(2):74-8. PubMed ID: 19024414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
    J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.
    Vergne L; Diagbouga S; Kouanfack C; Aghokeng A; Butel C; Laurent C; Noumssi N; Tardy M; Sawadogo A; Drabo J; Hien H; Zekeng L; Delaporte E; Peeters M
    Antivir Ther; 2006; 11(5):575-9. PubMed ID: 16964825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
    Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.